Exploring how certain antibodies affect kidney transplant outcomes in children
Understanding the Interface of Allo and Auto-Immunity: The Impact of Angiotensin II Type 1 Receptor Antibodies in Pediatric Kidney Transplant Recipients
This study is looking at how certain antibodies might affect the health and success of kidney transplants in kids, with the goal of finding better ways to help them after surgery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10662392 on NIH RePORTER |
What this research studies
This research investigates the role of angiotensin II type 1 receptor antibodies in pediatric kidney transplant recipients. The project aims to understand the balance between alloimmunity (immune response to transplanted tissue) and autoimmunity (immune response against one's own tissues) in these patients. By utilizing advanced statistical methods and clinical trial design, the research seeks to uncover how these antibodies impact kidney transplant success and patient health. The findings could lead to improved management strategies for children undergoing kidney transplants.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults under 21 who have received a kidney transplant.
Not a fit: Patients who have not undergone kidney transplantation or are over 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance kidney transplant outcomes and overall health for pediatric patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of antibodies in transplant outcomes, suggesting this approach has potential for success.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Pearl, Meghan Haley — University of California Los Angeles
- Study coordinator: Pearl, Meghan Haley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.